Overcoming paclitaxel resistance in uterine endometrial cancer using a COX-2 inhibitor

Oncology Reports

Volumn 30, Issue 6, 2013, Pages 2937-2944

  Hasegawa, Kiyoshi ^a   Ishikawa, Kunimi ^b   Kawai, Satoshi ^c   Torii, Yutaka ^c   Kawamura, Kyoko ^c   Kato, Rina ^c   Tsukada, Kazuhiko ^a   Udagawa, Yasuhiro ^c  

^a FUJITA HEALTH UNIVERSITY   (Japan)

^b Kaseki Hospital   (Japan)

^c FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

COX 2; COX 2 inhibitor; Endometrial cancer; MDRI; Paclitaxel resistance

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ETODOLAC; MESSENGER RNA; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; PACLITAXEL; PROSTAGLANDIN E2; RHODAMINE 123;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL LEVEL; CELL STRAIN OMC 2; CELL STRAIN OMC 2P; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENDOMETRIUM CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; GENE INDUCTION; GENE REPRESSION; GENETIC ASSOCIATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; SUPERNATANT; UPREGULATION;

CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DRUG RESISTANCE, NEOPLASM; ENDOMETRIAL NEOPLASMS; ETODOLAC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; P-GLYCOPROTEIN; PACLITAXEL; RNA, MESSENGER;

EID: 84892387480     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2790     Document Type: Article

References (32)

1. Dannenberg AJ and Subbaramaiah K: Targeting cyclooxygenase- 2 in human neoplasia: rationale and promise. Cancer Cell 4: 431-436, 2003.
2. Hasegawa K, Ohashi Y, Ishikawa K, et al: Expression of cyclooxygenase- 2 in uterine endometrial cancer and anti-tumor effects of a selective COX-2 inhibitor. Int J Oncol 26: 1419-1428, 2005.
3. Genç S, Attar E, Gürdöl F, Kendigelen S, Bilir A and Serdaroǧu H: The effect of COX-2 inhibitor, nimesulide, on angiogenetic factors in primary endometrial carcinoma cell culture. Clin Exp Med 7: 6-10, 2007.
4. Wood NJ, Quinton NA, Burdall S, Sheridan E and Duffy SR: Exploring the potential chemopreventative effect of aspirin and rofecoxib on hereditary nonpolyposis colorectal cancer-like endometrial cancer cells in vitro through mechanisms involving apoptosis, the cell cycle, and mismatch repair gene expression. Int J Gynecol Cancer 17: 447-454, 2007.
5. Sooriakumaran P, Coley HM, Fox SB, Macanas-Pirard P, Lovell DP, Henderson A, et al: A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer. Anticancer Res 29: 1483-1488, 2009.
6. Hasegawa K, Torii Y, Ishii R, Oe S, Kato R and Udagawa Y: Effects of a selective COX-2 inhibitor in patients with uterine endometrial cancers. Arch Gynecol Obstet 284: 1515-1521, 2011.
7. Soriano AF, Helfrich B, Chan DC, et al: Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res 59: 6178-6184, 1999.
8. Hida T, Kozaki K, Ito H, et al: Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents. Clin Cancer Res 8: 2443-2447, 2002.
9. Altorki NK, Keresztes JL, Port JL, Libby DM, Korst RJ, Flieder DB, et al: Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 21: 2645-2650, 2003.
10. Lipton A, Campbell-Baird C, Witters L, Harvey H and Ali S: Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer. J Clin Gastroenterol 44: 286-288, 2010.
11. Aruajo AM, Mendez JC, Coelho AL, Sousa B, Barata F, Figueiredo A, et al: Phase II study of celecoxib with cisplatin plus etoposide in extensive-stage small cell lung cancer. Cancer Invest 27: 391-396, 2009.
12. Ratnasinghe D, Daschner PJ, Anver MR, et al: Cyclooxygenase-2, P-glycoprotein-170 and drug resistance: Is chemoprevention against multidrug resistance possible? Anticancer Res 21: 2141-2147, 2001.
13. Patel VA, Dunn MJ and Sorokin A: Regulation of MDR-1 (p-glycoprotein) by cyclooxygenase-2. J Biol Chem 277: 38915-38920, 2002.
14. Sorokin A: Cyclooxygenase-2: potential role in regulation of drug efflux and multidrug resistance phenotype. Curr Pharm Des 10: 647-657, 2004.
15. Zatelli MC, Luchin A, Piccin D, et al: Cyclooxgenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism. J Clin Endocrinol Metab 90: 5754-5760, 2005.
16. Zatelli MC, Luchin A, Tagliati F, et al: Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression. Endocr Relat Cancer 14: 1029-1038, 2007.
17. Fontaine M, Elmquist WF and Miller DW: Use of rhodamine 123 to examine the functional activity of P-glycoprotein in primary cultured brain microvessel endothelial cell monolayers. Life Sci 59: 1521-1531, 1996.
18. Hille S, Rein DT, Riffelmann M, et al: Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer. Anticancer Drugs 17: 1041-1044, 2006.
19. Zrieki A, Farinotti R and Buyse M: Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal Caco-2 cell line. Pharm Res 25: 1991-2001, 2008.
20. Fantappiè O, Masini E, Sardi I, et al: The MDR phenotype is associated with the expression of COX-2 and iNOS in a human hepatocellular carcinoma cell line. Hepatology 35: 843-852, 2002.
21. Raspollini MR, Amunni G, Villanucci A, Boddi V and Taddei GL: Increased cyclooxygenase-2 (COX-2) and P-glycoprotein-170 (MDR1) expression is associated with chemotherapy resistance and poor prognosis. Analysis in ovarian carcinoma patients with low and high survival. Int J Gynecol Cancer 15: 255-260, 2005.
22. Surowiak P, Materna V, Denkert C, et al: Significance of cyclooxygenase 2 and MDR1/P-glycoprotein coexpression in ovarian cancers. Cancer Lett 235: 272-280, 2006.
23. Xi H, Baldus SE, Warnecke-Eberz U, et al: High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. Clin Cancer Res 11: 8341-8347, 2005.
24. Saikawa Y, Sugiura T, Toriumi F, et al: Cyclooxygenase-2 gene induction causes CDDP resistance in colon cancer cell line, HCT-15. Anticancer Res 24: 2723-2728, 2004.
25. Yamada T, Ueda M, Maeda T, et al: Establishment and characterization of CA125 producing cell line (OMC-2) originating from a human endometrial adenocarcinoma. Asia Oceania J Obstet Gynecol 15: 403-416, 1989.
26. Puhlmann U, Ziemann C, Ruedell G, et al: Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells. J Pharmacol Exp Ther 312: 346-354, 2005.
27. Chen C, Shen HL, Yang J, Chen QY and Xu WL: Preventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxib. J Cancer Res Clin Oncol 137: 9-17, 2011.
28. Bentires-Alj M, Barbu V, Fillet M, et al: NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 22: 90-97, 2003.
29. Daschner PJ, Ciolino HP, Plouzek CA and Yeh GC: Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells. Breast Cancer Res Treat 53: 229-240, 1999.
30. van Wijngaarden J, van Beek E, van Rossum G, et al: Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-κB-mediated increase of intracellular doxorubicin accumulation. Eur J Cancer 43: 433-442, 2007.
31. Bassiouny AR, Zaky A and Neenaa HM: Synergistic effect of celecoxib on 5-fluorouracil-induced apoptosis in hepatocellular carcinoma patients. Ann Hepatol 9: 410-418, 2010.
32. Sui H, Zhou S, Wang Y, et al: COX-2 contributes to P-glycoproteinmediated multidrug resistance via phosphorylation of c-Jun at Ser63/73 in colorectal cancer. Carcinogenesis 32: 667-675, 2011.